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Abstract 
Background: Multiple sclerosis is caused by an autoimmune response resulting in demyelination and neural 
degeneration. The adult central nervous system has the capacity to remyelinate axons in part through the genera‑
tion of new oligodendrocytes (OLs). To identify clinical candidate compounds that may promote remyelination, we 
have developed a high throughput screening (HTS) assay to identify compounds that promote the differentiation of 
oligodendrocyte precursor cells (OPCs) into OLs.
Results: Using acutely dissociated and purified rat OPCs coupled with immunofluorescent image quantification, we 
have developed an OL differentiation assay. We have validated this assay with a known promoter of differentiation, 
thyroid hormone, and subsequently used the assay to screen the NIH clinical collection library. We have identified 
twenty‑seven hit compounds which were validated by dose response analysis and the generation of half maximal 
effective concentration (EC50) values allowed for the ranking of efficacy. The assay identified novel promoters of OL 
differentiation which we attribute to (1) the incorporation of an OL toxicity pre‑screen to allow lowering the concen‑
trations of toxic compounds and (2) the utilization of freshly purified, non‑passaged OPCs. These features set our assay 
apart from other OL differentiation assays used for drug discovery efforts.
Conclusions: This acute primary OL‑based differentiation assay should be of use to those interested in screening 
large compound libraries for the identification of drugs for the treatment of MS and other demyelinating diseases.
Keywords: Myelination, Oligodendrocyte, High throughput, Drug screening, Differentiation, Primary cell‑based assay, 
Image analysis, Multiple sclerosis, Myelin basic protein
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Background
Multiple sclerosis (MS) is a devastating neurological 
disease, affecting over 2 million patients worldwide, 
caused by autoimmune-mediated destruction of the 
myelin sheaths that insulate and protect axons in the 
central nervous system. Most MS patients initially pre-
sent with the relapsing-remitting form of MS (RRMS), in 
which cycles of immune-mediated axonal demyelination 
(relapse) are followed by periods of remyelination (remis-
sion). Over time, however, the majority of RRMS patients 
exhibit chronic, progressive decline in neurological func-
tion. This is believed to be the result of an accumulation 
of axonal damage, as well as an eventual loss of remy-
elination capacity [1]. Although current MS therapies 
for RRMS provide significant relief from relapse, none 
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have yet been demonstrated to prevent disease progres-
sion and none have been effective in treating progres-
sive forms of MS. All of the disease-modifying therapies 
approved for treatment of RRMS do so by targeting the 
pathologic immune response [2]. Currently, there are no 
therapies that function to directly protect or restore mye-
lin, and identifying such therapies has been the focus of 
several groups in the field [3–7].
We have developed a high throughput drug screening 
assay to identify new therapeutic agents that accelerate 
the differentiation of immature OPCs into mature, mye-
lin-producing OLs. The hope is that these newly differ-
entiated OLs will accelerate the remyelination of axons 
following an immune attack. Here, we report the results 
of our screening campaign to identify drugs that stimu-
late oligodendrocyte differentiation. It is noteworthy that 
the assay that we employed differs in some details from 
those reported by others including (1) an OL toxicity 
prescreen which enabled lowering the concentrations of 
toxic compounds and (2) the utilization of freshly puri-
fied, non-passaged OPCs. We have screened the NIH col-
lection of known drugs—a library of 727 drugs that have 
been approved for the treatment of various indications. 
Our screening efforts confirmed the activity of several 
drugs identified by other groups [3, 6, 7]. More impor-
tantly, we report the identification of a number of novel 
OL differentiation-promoting compounds not previously 
detected in other screening campaigns.
Findings
Development of an oligodendrocyte differentiation assay 
using acutely purified OPCs
In order to identify compounds with the potential to 
promote OL differentiation in  vivo and thereby enhance 
remyelination, we first wanted to establish an in  vitro 
assay system that would closely mimic conditions in vivo. 
To do this, we started by using OPCs acutely isolated 
from postnatal day 6–7 (P6–7) rat brains by O4 immuno-
panning [8]. This allowed us to obtain an enriched popu-
lation of primary OPCs that could be used directly in cell 
culture assays without the need for extensive passaging 
and expansion in vitro. OPCs were plated directly onto a 
biological substrate (PDL/laminin) in 96-well view plates 
at moderate density to allow for sufficient room to expand 
processes during differentiation. We plated cells in serum-
free medium lacking OPC mitogens (no PDGF or FGF) to 
allow a basal level of OL differentiation to commence, and 
as a positive control added thyroid hormone (T3, 40 ng/
ml) to accelerate differentiation (Fig. 1, flow scheme) [9]. 
We found that T3 was able to consistently and signifi-
cantly promote OL differentiation over the 0.1 % DMSO 
negative control, as measured by MBP expression after 
4–5 days in culture in these conditions (Fig. 2a, b).
To quantify the extent of OL differentiation occurring 
in treatment conditions, we measured the overall amount 
of MBP expression/cell (see “Methods” section). Fig-
ure 2a depicts the mask created over MBP staining under 
which the MBP expression was quantified. The calculated 
MBP expression (OL differentiation) was then scaled to 
internal plate negative (0.1 % DMSO, set to 0) and posi-
tive (40  ng/ml T3, set to 100) control wells to generate 
percent OL differentiation score relative to the efficacy 
of positive control T3. This analysis of OL differentiation 
generated consistently significant results when T3 was 
compared to the DMSO negative control (Fig. 2b, inset). 
We used this analysis to determine the T3 dose response 
relationship and the EC50 value of 3.75 pg/ml (Fig. 2c).
OL toxicity assessment of the NIH Clinical Collection (NCC) 
library of known drugs
Having established a consistent assay for measuring OL 
differentiation in  vitro, the next step was to utilize this 
Fig. 1 Flow scheme of the acute OL differentiation assay. a Purified oligodendrocyte precursor cells (OPCs) were cultured from P7 rat cortex and 
plated into PDL/laminin pre‑coated 96‑well plates. b One hour later test compounds were added. c OPC cultures with compound were maintained 
in culture for an additional 4 days. d On the 5th day with compound, cells were fixed and immunostained with anti‑MBP antibodies and DAPI. e 
Images were acquired with automated fluorescence microscopy and scored phenotypically for OL differentiation (see “Methods” section)
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assay to assess the ability of a wide array of compounds 
to promote OL differentiation. Prior to library screen-
ing, we first established the maximum non-toxic dose 
of each compound in the library. Our rationale was that 
there may be a number of compounds that could be toxic 
to OPCs cultured in serum-free media when applied at 
high doses, but which may be beneficially active at lower 
doses. Consequently, these beneficial activities would 
be missed if compounds were only tested at high, toxic 
doses. Therefore, we added each compound in the NIH 
clinical collection (NCC) library to OPCs at 10, 1, and 
0.1  µM concentrations. Three days later, we assessed 
viability of the treated cells by measuring AlamarBlue 
fluorescence, a measure of cell viability (see “Methods” 
section). We found that 17.7 % of the compounds tested 
were significantly toxic to cultured OPCs at 10 µM, but 
non-toxic at lower doses. An additional 9.5  % of tested 
compounds were significantly toxic even at lower tested 
Fig. 2 Acute OL differentiation assay quantification and validation. a Left panels, Full field images of acutely isolated and purified OPCs were 
differentiated for 4 days in the presence or absence of thyroid hormone (T3) and immunostained with anti‑MBP antibodies. Center panels, digital 
masks were created using IN Cell software depicting the extent of threshold MBP staining of the images at left. Right panels, DAPI stained nuclei of 
the identical image filed at left. Bar = 200 µm. b The dose response activity of T3. Asterisk (*) denotes P values versus DMSO of <0.05, t test. Inset, 
the consistency and significance of T3 activity taken from eight independent plates. c The dose response curve and EC50 determination for T3 OL 
differentiation‑promoting activity was calculated (16 fields per concentration, mean ± SEM)
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doses (Additional file  1: Table S1). Appropriately, we 
established three sets of screening concentrations for 
library compounds: non-toxic compounds were tested 
at 10 and 2 µM, slightly toxic compounds (only toxic at 
10 µM) were tested at 2 and 0.4 µM, and very toxic com-
pounds were tested at 0.4 and 0.08 µM.
NCC library screening for compounds that promote OL 
differentiation
Screening the NCC library of 727 known and FDA-
approved drugs allowed us to test structurally distinct 
compounds with known safety profiles and biological 
activity in humans. Having established the peak non-
toxic doses at which to test the NCC library compounds, 
we next screened this library using the acute OL differen-
tiation assay. All compounds were tested at two concen-
trations, with positive (T3) and negative (0.1  % DMSO) 
control wells included on each assay plate. Additional 
file 2: Table S2 contains all of the acute OL differentiation 
assay NCC library screening data.
Hits were classified as compounds that increased OL 
differentiation from baseline to at least 50 % of T3-pro-
moted levels. To evaluate efficiency and validity of our 
screening method, we used a scatter plot to visualize 
compounds relative to three standard deviations (SD) 
from the mean (Fig.  3a). While not a criterion in our 
assay for hit selection, it provided a common statistical 
assurance that we were well out of false-positive hit rate 
(0.15  %) range. This was also confirmed visually when 
plotted alongside our ≥50  % T3 threshold (Fig.  3b). 
Positive control T3 versus DMSO values from the entire 
screen for OL differentiation were highly statistically 
significant per assay plate (Fig. 3b, c) and averaged over 
entire screen (Fig. 3c, inset) as well as robust (overall Z 
prime  =  0.2), indicating an acceptable screen window 
and reproducibility. We identified 36 actives (5  % pri-
mary hit rate) able to promote OL differentiation at one 
or both concentrations tested (Fig. 3d; Additional file 2: 
Table S2). Two of these compounds were T3 and the T3 
precursor thyroxine (T4), known promoters of OL differ-
entiation, and thus not followed up in future studies.
Independent confirmation and validation of identified hits
We next confirmed the differentiation-promoting activity 
of the 34 remaining identified compounds. We obtained 
all 34 hit compounds from various independent vendors 
to test in our OL differentiation assay. All compounds 
were tested at eight concentrations in at least two bio-
logical replicate experiments to generate dose-response 
curves for each candidate hit compound. Of the 34 initial 
hit compounds tested in this way, 26 (72 % hit confirma-
tion rate) reproducibly promoted OL differentiation in 
a dose dependent manner (Table  1; Figs.  4, 5, 6, 7, 3d). 
Analysis of the EC50 values for each compound enabled 
the ranking of compound within each class. The average 
potency EC50, ranged from 30  nM to >20  µM (Table  1; 
Figs. 4, 5, 6, 7). Figures 4, 5, 6, 7 show each hit compound 
with the chemical structure, a representative MBP/DAPI 
screening image demonstrating numbers of OLs/field 
and OL morphology, and a representative OL differen-
tiation EC50 curves. Table  1 shows the calculated aver-
age EC50 values for induction of differentiation obtained 
from independent biological replicates for the top hits 
from our initial OL differentiation screen. Based on the 
available literature on these previously characterized 
compounds, we grouped the hits by known mechanisms 
of action. Notably, our OL differentiation screen identi-
fied compounds from several distinct drug classes. Some 
of the hit compounds had been independently identified 
by other OL differentiation screening paradigms [3, 6, 
7] (Table  2), whereas the refinement of using a toxicity 
prescreen and performing the assay on acutely purified 
OPCs allowed us to identify 16 additional novel compou
nds.
Although we observed that all actives could promote 
not only MBP expression, but also a morphological shift 
typical to OL differentiation (Figs.  4a–h, 5 i–p, 6q–x, 
7y–c1), we nonetheless confirmed that active compounds 
could promote other markers of OL differentiation. In 
addition to MBP, we tested the ability of the 27 confirmed 
hit compounds to promote expression of 2′, 3′-cyclic-
nucleotide 3′-phosphodiesterase (CNPase) and Galac-
tocerebroside (GalC), two additional established markers 
of OL differentiation [10, 11]. All 27 confirmed hit com-
pounds promoted CNP and GalC in our acute OL differ-
entiation assay (Additional file 1: Figure S1A, B is shown).
Discussion
Development of an acute OL differentiation compound 
screening assay
In an effort to identify possible therapeutic candidate 
compounds for multiple sclerosis and other demyelinat-
ing diseases, we have developed novel oligodendrocyte 
assays amenable to high throughput screening. We have 
established the first OL differentiation assay to utilize 
freshly purified, unpassaged OPCs. This distinguishes 
our assay from other OL differentiation assays used for 
drug discovery efforts, which used highly passaged OPCs 
or iPS-derived OPCs. Additionally, we used an OL toxic-
ity pre-screening assay to customize our library screen-
ing efforts to account for compounds that may be toxic 
at high concentration, but efficacious at lower concen-
trations. This is an unusual precaution to take, as it is 
standard practice to screen an entire library at a single 
concentration (e.g., 10 µM) to minimize labor and time. 
Such a library is thus very different than a typical HTS 
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library composed of novel, unknown and un-optimized 
compounds. This approach proved fruitful, as we iden-
tified several OL differentiation-promoting drugs in the 
NCC library that were not identified in another screen 
[7] that used this same library. Below is a discussion of 
some of the top hit compounds identified from our OL 
differentiation assay and their possible relevance to mul-
tiple sclerosis.
Other in vitro OL differentiation assays used for com-
pound screening have only assessed differentiation using 
purified OPCs adapted to culture conditions by multiple 
passages [3], or differentiated from induced pluripotent 
stem cells [7]. Mei et al. developed an HTS assay incorpo-
rating OL differentiation in the presence of inert micro-
pillars allowing the quantification of pillar wrapping as a 
surrogate for myelination [6]. We have noted the techni-
cal similarities and differences of our OL differentiation 
assay with these other studies in Table 2. The lead com-
pounds that overlap with our findings are summarized 
in Table 3 and represent only about half of the leads we 
identified (in particular, the tricyclic anti-depressants and 
muscarinic drug classes), with the remaining compounds 
being identified and reported for the first time in our 
screen.
It should be noted that this in vitro OL differentiation 
screening assay only identifies compounds that promote 
OL differentiation and does not address whether the dif-
ferentiated OLs also promote myelination. Additionally, 
this assay is performed in purified monoculture absent 
of other cell types that influence OL differentiation and 
myelination, e.g. neurons and astrocytes. Furthermore, 
this assay is performed under ideal OL differentiation 
conditions, unlike the inflammatory conditions present 
demyelination lesions. One should also be aware that 
the compounds identified in this screen have only been 
tested on rat OPCs. Mei et  al. demonstrated cross-spe-
cies compound activity in their OL differentiation assay, 
however, compounds identified from our OL differentia-
tion screen have not been verified on mouse or human 
cells. Testing these compounds on OLs derived from 
Fig. 3 Analysis of the acute OL differentiation screen of the NCC compound library. a Dot plot representation of the entire high‑throughput screen‑
ing data set used to identify promoters of OL differentiation. Highlighted are the primary hit compound (red) activity. The mean response is indi‑
cated by the blue solid line. The black dotted line delineates the value of three standard deviations above the mean. The red dotted line delineates the 
≥50 % positive control selection criteria. b Scatter plot representation of the high‑throughput screening assay window. Using the T3/DMSO ratio as 
the window of measurable OL differentiation, the ratio of the positive (T3) to negative (DMSO) controls is depicted. The red line delineates the mean 
average ratio value for the entire NCC library screen = 3.1. The numbers above the scatter indicate the coefficient of variation (CV) for each plate. 
CV values <20 ± 5 were considered in the acceptable range. Each point is an average value from 16 fields. Each dot cluster represents eight control 
ratios from each NCC plate (n = 8, mean ± SEM). c Average raw values of DMSO and T3 for each library screening plate. Inset, The statistical analysis 
of the raw values of controls from all plates of the entire NCC library screen. d Summary of hit selection from the NCC library screen
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human iPSCs would greatly increase the potential thera-
peutic value of these compounds. Nevertheless, OL dif-
ferentiation-promoting compounds have the potential to 
increase the number of myelination competent OLs and 
therefore facilitate myelination. This hypothesis has been 
supported by the previously published work mentioned 
above that have identified pro-OL differentiating com-
pounds that have facilitated myelination in vivo [3, 6, 7].
Confirmed hits group into multiple mechanistic classes
We found that the hits identified in the OL differentia-
tion assay (Table 1) could be assigned into six broad cat-
egories, falling into common functional or structural 
categories. We have grouped these compounds into pos-
sible signaling pathways that feed into OL differentiation 
(Fig. 8).
Benztropine, donepezil, oxybutynin, vesamicol, and 
ipratropium all perturb the muscarinic acetylcholine 
signaling pathway. Indeed, the muscarinic receptor path-
way has been previously implicated in OL differentia-
tion and benztropine, oxybutynin and ipratropium were 
identified in other OL differentiation screens [3, 6, 7] (see 
Table  2, comparison). To supplement this class, we also 
tested clemastine, another muscarinic receptor antago-
nist characterized by Mei et al. [6] and found it too could 
promote OL differentiation in our assay similar to ben-
ztropine (Table  1; Figs.  4, 5, 6, 7; Additional file  1: Fig-
ure S1A). Both benztropine and clemastine have shown 
efficacy in stimulating remyelination in in vivo models [3, 
6]. Previous work has demonstrated that M2 muscarinic 
receptor agonism has mitogenic activity increasing 
PDGFR∝ expression to keep OPCs in a proliferative state 
[12]. Further, it was recently shown that treatment with 
solifenacin, an FDA-approved M3 muscarinic receptor 
antagonist, promoted oligodendrocyte differentiation 
of transplanted hOPCs in hypomyelinated shiverer/rag2 
brain [13].
A second compound class uniquely identified by our 
OL differentiation assay was the selective estrogen recep-
tor modulators (SERMs): raloxifene, toremifene, and 
tamoxifen. These compounds may be acting through 
the estrogen β receptor (EβR) and the PI3 K/Akt/mTOR 
signaling pathway, previously shown to stimulate OL dif-
ferentiation and remyelination in  vivo in demyelinating 
animal models of MS [14–18].
A third compound class includes perphenazine, 
prochlorperazine, fluphenazine, trifluorperazine, and 
QTP: five tricyclic antidepressant molecules with struc-
tural similarity believed to act primarily as serotonin/
norepinephrine reuptake inhibitors (SNRIs) by blocking 
the serotonin transporter (SERT) and the norepinephrine 
transporter (NET). It must also be noted that these com-
pounds also have significant off-target activity, including 
muscarinic antagonistic activity among others, which 
may account for OL differentiation-promoting activity. 
Perospirone, escitalopram, citalopram, metylperon, and 
bupropion are loosely grouped together as a class of non-
tricyclic antidepressants that, with the exception of esci-
talopram and citalopram, do not share much structural 
similarity. These compounds have the properties of being 
selective serotonin reuptake inhibitors (SSRIs—escit-
alopram, citalopram, bupropion) or dopamine receptor 
antagonists (perospirone, metylperon). Since OPCs/pre-
myelinating OLs express SERTs, NETs, serotonin recep-
tors, and dopamine receptors [19], it is possible that the 
antidepressant class of compounds may function by mod-
ulating neurotransmitter levels and/or neurotransmitter 
receptor activity to facilitate OL differentiation [20].
Table 1 Confirmed acute OL differentiation hits from  the 
NCC library screen
ND no data. DMPP dimethylphenylpiperazinium
a Values indicate percent positive control
b Not part of the NCC library screen
Drug class Compound OL differentiationa EC50, μM






















Adrenergic Salmeterol 52 0.4
Betaxolol 86 4.2
Esmolol 65 240





Anti‑fungal Bifonazole 66 1.7
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Salmeterol, betaxolol, and esmolol all interact with the 
adrenergic receptor (AR) pathway [21]. There is a pau-
city of data on AR function in OL differentiation. ARs are 
expressed in OL precursors [19] and the ∝1-AR has been 
demonstrated to play a role in OL specification and dif-
ferentiation in vivo [22].
Finally, a broad class of ion channel modulators was 
identified: ifenprodil, benproperine, proxymetacaine, 
dofetilide, and dimethylphenylpiperazinium (DMPP). 
DMPP acts through the stimulation of the nicotinic ace-
tylcholine receptor (nAChR) which may play a role in 
OL differentiation. Interestingly, it was recently dem-
onstrated that donepezil-induced OL differentiation 
was mediated by the nACHR. Ifenprodil is an NMDA 
receptor (NMDAR) antagonist. It has been shown 
that NMDARs are present in precursor, immature and 
mature OLs [23, 24]. One additional active compound, 
bifonazole, is a known antifungal agent. A number of 
azole-containing anti-fungals have known effects on ion 
channels [25], but it is not known what role these may 
have in OL differentiation. By interacting with ion chan-
nels, these compounds may alter intracellular ion levels 
within OPCs/pre-myelinating OLs to facilitate OL differ-
entiation [26].
Relevance to multiple sclerosis
There are many examples where repurposed drugs are 
making an impact in the field of MS. A few of note are 
BG-12 (Tecfidera®), a modification of a psoriasis drug; 
fingolimod (Gilenya®), originally developed for trans-
plantation and alemtuzamab (Lemtrada™), originally an 
oncology drug. We found that a fair number of our hits 
aligned with current MS repositioning efforts in terms 
of patents, preclinical work, and clinical trials and are 
briefly cited here.
The SERMs represent a promising new class of com-
pounds that promote OL differentiation not identified in 
other screens. Modulation of the estrogen receptor has 
been demonstrated to be effective in preventing demyelina-
tion in vivo and to stimulate differentiation and remyelina-
tion [27–30]. Specifically, raloxifene (Evista®) was shown to 
be effective in suppressing EAE [31]. The pregnancy hor-
mone estriol (Trimesta™) has shown efficacy in a clinical 
trial of MS reducing the lesion numbers and volumes [32].
Fig. 4 Structures, images, and EC50s of OL differentiation hits. a–h first column, Chemical structures and names of each hit compound and the 
controls, 0.1 % DMSO and T3. a–h second column, Example images of each hit compound directly from the library screening plate at the most 
efficacious concentration showing MBP (green) and DAPI (blue) staining. Bar = 200 µM. a–h third column, Representative OL differentiation dose–
response curves used for computing the EC50 of each hit compound
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A number of hits that we identified are covered in pat-
ents for oligodendrocyte directed differentiation. Notably 
trifluoperazine (Stelatzine®), benztropine (Cogentin®), 
and ipatropium (Atrovent®) are patented for the use of 
neurotransmitter receptor modulating agents for induc-
ing OL differentiation, as well as methods for treating 
subjects with such agents in a demyelinating disease.
Other hits have been evaluated or will soon be tested in 
human MS trials. QTP (Seroquel XR®), an antipsychotic 
approved for schizophrenia is currently in clinical trials to 
determine tolerability to people with relapsing remitting 
multiple sclerosis (RRMS) and progressive MS (Clinical-
trials.gov identifier: NCT02087631). Selective serotonin 
re-uptake inhibitors (SSRIs) such as nitalapram (Celexa®) 
and escitalopram (Lexapro®) have also been in human 
MS trials. Nitalapram is one of three other SSRIs tested 
as an add-on with fingolimod, a current immunomodu-
latory treatment for MS (REGAIN Trial NCT01436643) 
in RRMS patients with depression. Escitalopram has 
been in a study to test improvement of depression in 
patients of MS or ALS (Trial NCT00965497). Donepezil 
(Aricept®), used as a treatment for dementia, has been 
used in a study to improve cognitive dysfunction in MS 
patients (NCT00315367) [33–35]. Oxybutynin (Ditro-
pan XL®) is used currently in symptom management 
for MS to treat overactive bladder in MS (SONIC trial 
NCT00629642). Clemastine fumarate (Tavist®) originally 
approved as a first-generation antihistamine, is active 
in a current study to assess the drug as a remyelinating 
agent is RRMS patients (ReBUILD trial NCT02040298). 
Though not a hit in our screen, albuterol (compound 
#4, Additional file  3: Table S2), a short acting β2 adr-
energic receptor agonist, was tested in a clinical trial 
(Trial NCT00039988) as an add-on therapy to capaxone 
(glatiramir acetate) for patients with RRMS and showed 
improved clinical outcomes. Perhaps the longer acting β2 
adrenergic receptor agonist, salmeterol, which we identi-
fied in our screen, may also provide some clinical efficacy.
To our knowledge, the remainder of our confirmed hits 
has not been tested in any demyelinating diseases.
Conclusion
We have demonstrated here an OL differentiation assay 
with the robustness, scale and reproducibility amenable 
to HTS drug discovery. The assay was designed to pre-
serve primary cell, in vivo-like characteristics in culture 
Fig. 5 Structures, images, and EC50s of OL differentiation hits. i–p first column, Chemical structures and names of each hit compound and the 
controls, 0.1 % DMSO and T3. i–p second column, Example images of each hit compound directly from the library screening plate at the most 
efficacious concentration showing MBP (green) and DAPI (blue) staining. Bar = 200 µM. i–p third column, Representative OL differentiation dose–
response curves used for computing the EC50 of each hit compound
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by using only acutely isolated cells (OL differentiation 
assay) and limited subculture to a single expansion (OL 
toxicity assay). Thus, we avoided undesirable changes in 
cellular phenotype (e.g. gene expression and/or unsta-
ble karyotypes) that multiple cell passages or derivation 
from large-scale stem cell cultures may introduce [3, 7, 
36, 37]. Additionally, the OL toxicity pre-screen allowed 
us to reduce the top concentrations of toxic compounds 
and was essential to identifying compounds that were 
more efficacious at lower concentrations. Future studies 
should focus on testing these novel OL differentiation-
promoting compounds both in vitro with human cells as 
well as in vivo models of MS. Furthermore, this assay is 




High glucose Dulbecco’s modified eagle medium 
(DMEM), neurobasal medium (NB), Earle’s balanced salt 
solution (EBSS), l-glutamine, fetal bovine serum (FBS), 
penicillin/streptomycin, sodium pyruvate, diamidino-
2-phenylindole, dilactate (DAPI) were purchased from 
life technologies (Carlsbad, CA, USA). Normal goat 
serum, forskolin, triiodothyronine (T3, thyroid hor-
mone), vitamin B12, hydrocortisone, d-biotin, apotrans-
ferrin, putrescine, progesterone, sodium selenite, 
poly-d-lysine (PDL), recombinant human (rh) insulin, 
bovine serum albumin, N-acetyl-l-cysteine, sodium 
phosphate (mono- and dibasic), sodium chloride, tris 
base, l-lysine, sodium azide, tunicamycin and DMSO 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Trace elements B, Dulbecco’s phosphate buffer saline 
(dPBS) and trypsin 0.05  %-EDTA were purchased from 
Mediatech, Inc. (Manassas, VA, USA). Human cerulo-
plasmin was purchased from EMD Millipore (Billerica, 
MA, USA). Recombinant rat (rr) CNTF, rrIFNγ, rrTNFα, 
rhNT-3 and rhPDGF-AA were purchased from Pepro-
Tech (Rock Hill, NJ, USA). Laminin was obtained from 
Trevigen (Gaithersburg, MD, USA). DNase, papain and 
ovomucoid inhibitor were purchased from Worthing-
ton Biochemical Corporation (Lakewood, NJ, USA). 
Paraformaldehyde solution was purchased from Elec-
tron Microscopy Science (Hatfield, PA). alamarBlue® 
(AB) was purchase from AbD Serotech (Killington, UK). 
Packard 96-well Viewplates were purchased from Perkin 
Fig. 6 Structures, images, and EC50s of OL differentiation hits. q–x first column, Chemical structures and names of each hit compound and the 
controls, 0.1 % DMSO and T3. q–x second column, Example images of each hit compound directly from the library screening plate at the most 
efficacious concentration showing MBP (green) and DAPI (blue) staining. Bar = 200 µM. q–x third column, Representative OL differentiation dose–
response curves used for computing the EC50 of each hit compound
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Elmer (Waltham, MA, USA). Falcon TC 96-well plates 
were purchase from corning (Corning, NY). Additional 
file 4: Table S3 lists the primary antibodies and their dilu-
tions used in this study.
Compounds
All compounds in the NIH Clinical Collection (NCC) 
library were supplied in DMSO at 10  mM in 96-well 
plates. Hit compounds were purchased as powders and 
stock solutions were dissolved in DMSO to 10 mM (see 
Additional file 2: Table S1, Additional file 3: Table S2 for 
complete listing of compounds).
Isolation and culture of neonatal rat OPCs
All animal work was carried out in strict accordance 
with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Insti-
tutes of Health. The protocol was approved by the 
Institutional Use and Care and Use Committee at the 
Molecular Medicine Research Institute (Sunnyvale, CA). 
Animals used for OPC isolation in these studies were 
euthanized by decapitation. OPCs from brains of P6-P7 
Sprague–Dawley rat pups (Charles River, Wilmington, 
MA, USA) were enriched by immunopanning as previ-
ously described (Dugas et  al. 2006). Briefly, single cell 
suspensions were obtained from papain-digested neona-
tal brains and depleted of mature glial cells by successive 
panning with RAN-2- and GalC-coated plates, followed 
by enrichment for OPCs using O4-coated plates. OPCs 
were plated in differentiation media (DMEM, 100  U/ml 
Penicillin/100  µg/ml streptomycin, 2  mM  l-glutamine, 
1 mM Na pyruvate, 5 µg/ml insulin, 5 µg/ml N-acetyl-l-
cysteine, 1× trace elements B,10 ng/ml d-Biotin, 100 µg/
ml BSA, 100 µg/ml apo-transferrin, 16 µg/ml putrescine, 
60 ng/ml progesterone, 40 ng/ml sodium selenite 5 ng/ml 
forskolin, 10 ng/ml CNTF, 1 ng/ml NT-3).
Fig. 7 Structures, images, and EC50s of OL differentiation hits. y–c
1 
first column, Chemical structures and names of each hit compound 
and the controls, 0.1 % DMSO and T3. y–c1 second column, Example 
images of each hit compound directly from the library screening 
plate at the most efficacious concentration showing MBP (green) and 
DAPI (blue) staining. Bar = 200 µM. y–c1 third column, Representative 
OL differentiation dose–response curves used for computing the EC50 
of each hit compound
Table 2 Technical comparison of acute OL differentiation assay with other OL differentiation assays
a Myelin Repair Foundation, Translation Medicine Center
Technical details MRF-TMCa Deshmukh [3] Mei [6] Najm [7]
Pre‑toxicity screen ●
Rat OPCs ● ● ●
Mouse OPCs ● ●
Acutely‑derived ●
Passaged/expanded OPCs ● ●
iPSC‑derived OPCs ●
Cortex‑derived OPCs ● ●
Optic nerve‑derived OPCs ●
MBP/PDGFRα/micropillar wrapping analysis ●
MBP expression analysis ● ● ●
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Oligodendrocyte toxicity assay
OPCs were expanded in vitro by seeding into PDL-coated 
tissue culture flasks at 1000–2000  cells/cm2 in differen-
tiation media supplemented with 10  ng/ml PDGF-AA. 
Proliferating OPCs were fed every 2–3 days and supple-
mented with 2–3× concentration of PDGF as needed to 
prevent OPC differentiation. After 6–7 days of prolifera-
tion, OPCs were harvested by trypsinization, plated into 
PDL-coated 96-well Falcon plates and centrifuged at 
200×g to facilitate cell attachment, survival, and even dis-
tribution of cells. Expanded OPCs were seeded in differ-
entiation media at 10,000 cells/well and incubated for 2 h 
at 37 °C, 10 % CO2 prior to addition of compounds. The 
NCC library was diluted and added to cells at 10, 1, and 
0.1 µM; each concentration was tested in quadruplicate. 
As a positive control for the induction of toxicity, 5 ng/
ml tunicamycin was added to 8 wells in each plate. Three 
days later, a 1:10 dilution of alamarBlue® (AB) was added 
to each well and cells were incubated 4 h at 37 °C, 10 % 
CO2. AB fluorescence was measured using a PerkinElmer 
Victor II fluorescence microplate reader (PerkinElmer, 
Waltham, MA) with 560 nm excitation/590 nm emission 
filters. For library screening, the highest concentration of 
each compound was adjusted to a minimally toxic con-
centration based on this toxicity data. Compounds were 
additionally tested at a second concentration that was 
1/5th of the top concentration. The final concentration of 
DMSO in each well was 0.1 %.
Acute oligodendrocyte differentiation assay
Acutely enriched OPCs were plated in differentiation 
media at 5000 cells/well into PDL/laminin coated 96-well 
Table 3 Comparison of  acute OL differentiation hits in  the NCC library with  hits reported in  other OL differentiation 
assays
a Myelin Repair Foundation, Translation Medicine Center
b Compound not part of the NCC library screen
Confirmed NCC library hits OL differentiation assays








Quetiapine ● ● ●




Muscarinic Benztropine ● ● ● ●
Donepezil ●
Vesamicol ● ●
Oxybutynin ● ● ●
Ipatropium ● ● ●
Clemastineb ● ● ●
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view plates and centrifuged at 200×g to facilitate cell 
attachment, survival, and even distribution of OPCs. OPCs 
were pre-incubated for 1–2  h at 37  °C in 10  % CO2, fol-
lowed by the addition of test compounds in quadruplicate. 
Controls were added in eight replicate wells, negative con-
trol = 0.1 % DMSO; positive control = 40 ng/ml T3. The 
day of OPC plating was considered DIV0. On DIV4, cells 
were fixed, immunostained for myelin basic protein (MBP) 
expression, imaged and quantified as described below.
Immunofluorescence staining and imaging
Following compound treatment, media was removed 
leaving 50  μl/well using an ELx405 microplate washer 
(BioTek, Winooski, VT, USA), the automated plate 
washer was also used for all subsequent washing steps 
during the staining. Cells were fixed for 14  min with 
4 % paraformaldehyde at room temperature (RT). Fol-
lowing fixation, plates were washed with 1  ml PBS 
leaving 50 μl/well. Cells were then incubated in block-
ing buffer (10  % normal goat serum (NGS) diluted in 
antibody buffer: 150 mM NaCl, 50 mM Tris Base, 1 % 
BSA, 100  mM l-lysine, 0.04  % sodium azide, pH 7.4), 
with 0.4  % Triton X-100 for 1  h at RT, then stained 
overnight at 4  °C with rat anti-MBP antibodies (Addi-
tional file  4: Table S3) diluted in blocking buffer with 
0.08 % Triton X-100. The cells were washed and incu-
bated with secondary antibodies and 0.3 μM DAPI for 
1 h at RT. After a final wash, 100 μl of PBS was added 
to each well and plates imaged. Images were captured 
with a Nikon Eclipse TE-2000-U microscope, Zyla 
cMOS megapixel camera (ANDOR Technology, Bel-
fast, UK), fitted with an automated stage controlled by 
NIS Elements AR software 4.0 (Melville, NY, USA). An 
air 10× lens was used to capture 2–4 images per well 
with 16 bit resolution, 2560 ×  2160 pixels. Images for 
each assay run were captured using identical camera 
settings. Images were exported as TIFF files for analysis 
and quantification.
Image quantification
TIFF files were analyzed using custom algorithms cre-
ated with IN Cell Investigator Developer Toolbox (GE 
Health Sciences, Piscataway, NJ, USA). For each well of 
OL differentiation assay, four images were analyzed per 
well and the data from the duplicate wells was combined 
and averaged (total of eight images per test condition). 
For cytokine protection assay, two images were analyzed 
per well and the data from triplicate wells was combined 
and averaged (total of six images per test condition). The 
overall amount of MBP expression/cell was quantified 
in each image by calculating the density × area of MBP 
staining, and normalizing to the total number of DAPI-
stained nuclei in the same field. The calculated extent of 
MBP expression (OL differentiation) was then scaled to 
internal plate negative (0.1  % DMSO) and positive con-
trols (40 ng/ml T3) to generate percent OL differentiation 
Fig. 8 Possible hit compound signaling pathways involved in OL differentiation and myelination. The 27 compounds identified from the acute OL 
differentiation screen were grouped into seven classes: muscarinic receptor antagonists, andrenergic agonists, tricyclic antidepressants, non‑tricyclic 
antidepressants, selective estrogen receptor modulators (SERMs), ion channel modulators and antifungals. Based on a literature review, these 
compound classes were further categorized into the most likely steps in OL development where compounds may be active. Note that some of 
the tricyclic antidepressents and non‑tricyclic antidepressents have off‑target muscarinic activity. Also note that the OL differentiation‑promoting 
mechanisms of these compounds may not necessarily act through the same mechanisms as the known FDA‑approved indication target
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scores relative to the efficacy of positive control. For the 
cytokine protection assay, the positive controls were 
either no insult or 1.1 μM QTP. This analysis consistently 
generated quantitatively similar results when scaled to 
internal plate negative and positive control wells.
Relative EC50 analysis
EC50 values were obtained by fitting the data to a sigmoi-
dal dose–response curve-fitting function (Prism, Graph-
Pad, San Diego, CA, USA). Serial dilutions of eight to ten 
different concentrations with three or four data points 
per concentration were used for curve fitting. Experi-
ments were repeated at least two times.
Statistical methods
For all experiments, assuming normal distribution, two-
tailed t-tests were used to evaluate comparisons between 
two groups.
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